1 PURPOSE
1.1 This procedure establishes the process for the convened IRB to institute a Suspension of IRB Approval or a Termination of IRB Approval.
1.2 The process begins when the convened panel disallows research approved by the Institution’s IRB or an external IRB and institutes a Suspension of IRB Approval or a Termination of IRB Approval.
1.3 The process ends after the Principal Investigator (PI) has been informed of the Suspension of IRB Approval or a Termination of IRB Approval.

2 PREVIOUS VERSION
2.1 Previous version dated 11/22/2018.

3 POLICY
3.1 The convened IRB may institute a Suspension of IRB Approval or a Termination of IRB Approval for some or all research activities on a protocol if the convened IRB determines the previously approved research is not being conducted in accordance with the Northwestern University IRB’s requirements or that the research has been associated with unexpected serious harm to participants.
3.2 Whenever possible the individual following these procedures promptly communicates with investigators in writing.

4 RESPONSIBILITIES
4.1 If the investigator suspends or terminates a research study without prior agreement of the sponsor, the investigator should promptly inform the sponsor and the IRB, and should provide a detailed written explanation of the suspension or termination via a Reportable New Information (RNI) application in the eIRB+ system.
4.2 If the sponsor suspends or terminates a trial, the investigator should promptly inform the institution by supplying the IRB with a detailed written explanation of the suspension or termination via an RNI application in the eIRB+ system.
4.3 In cases where the IRB suspends or terminates its approval determination of a study, the IRB Office will inform the investigator, and the investigator should promptly notify the sponsor and provide the sponsor with a detailed written explanation of the suspension or termination.

5 PROCEDURE
5.1 The convened IRB will assess a submission (such as a continuing review, modification, or reportable new information) that is under consideration.
5.2 The convened IRB will enter a separate motion for the assessment of the submission and vote to issue a Suspension of IRB Approval or Termination of IRB Approval.
5.3 The IRB Compliance Analyst will place the study in a suspended state in the eIRB+ system.
5.4 The IRB Compliance Analyst will complete and send the Principal Investigator by email and in the eIRB+ system a TEMPLATE LETTER: Suspension of IRB Approval (HRP-715) or TEMPLATE LETTER: Termination of IRB Approval (HRP-716) to notify the investigator of the Suspension of IRB Approval or Termination of IRB Approval and the reasons for the decision in writing.
5.5 The Compliance Analyst will send a copy of the suspension / termination letter to the IRB Office Executive Director, the Principal Investigator’s department chair or division chief, and entity administrators via email.
5.6 The IRB Compliance Analyst will notify the IRB Analyst of the Suspension of IRB Approval or Termination of IRB Approval by email.
5.7 The Principal Investigator may ask the Chair to allow actions that are required to protect participants’ rights and welfare or to eliminate an apparent immediate hazard.

5.8 The convened IRB will consider whether any of the following additional actions are required to protect participants’ rights and welfare or to eliminate an apparent immediate hazard:

5.8.1 Transferring participants to another investigator.
5.8.2 Arranging for clinical care outside the research.
5.8.3 Allowing continuation of some research activities under the supervision of an independent monitor.
5.8.4 Requiring or permitting follow-up of participants for safety reasons.
5.8.5 Requiring adverse events or outcomes to be reported to the IRB and the sponsor.
5.8.6 Notification to current participants.
5.8.7 Notification to former participants.

5.9 The IRB Analyst will issue a determination letter for the submission under review.

5.9.1 If any other submissions for the study, such as a modification, continuing review, Reportable New Information, are under review, a member of the Compliance Team will contact the IRB Analyst assigned to the submission to ensure that no approvals are issued after the study is terminated or until the suspension is lifted.

5.10 Should the Principal Investigator wish to respond or need additional information, the Principal Investigator or designee may contact the IRB Compliance Team. To lift the suspension, the Principal Investigator (PI) must submit a formal response to the suspension letter via email to irbcompliance@northwestern.edu.

5.11 A member of the IRB Compliance Team will instruct the Principal Investigator regarding the next appropriate steps, which will include submission of an RNI in eIRB+, or other applicable action.

5.12 The convened IRB panel that instituted the suspension will review the response and provide a determination.

5.13 The IRB Analyst will issue a determination letter for the RNI under review.

5.14 If the Principal Investigator wishes to reinstate a terminated study, the PI must submit a new study application and include in the application a formal response to the issues outlined in the termination letter.

5.15 A member of the IRB Compliance Team will report the suspension or termination to institutional officials and the applicable federal agencies such as the Office of Human Research Protections (OHRP) and the Food and Drug Administration (FDA) using the procedures outlined in the External Reporting Process SOP (HRP-094), and at the next IRB Chairs meeting.

6 MATERIALS

6.1 GENERAL DOCUMENT: Human Research Protection Program Plan (HRP-101)
6.2 GENERAL DOCUMENT: Investigator Manual (HRP-103)
6.3 SOP: External Reporting (HRP-094)
6.4 SOP: Suspension or Termination Issued Outside of Convened IRB (HRP-026)
6.5 TEMPLATE LETTER: Suspension of IRB Approval (HRP-715)
6.6 TEMPLATE LETTER: Termination of IRB Approval (HRP-716)

7 REFERENCES

7.1 21 CFR §56.108(b)(3), 21 CFR §56.113
7.2 45 CFR §46.103(b)(5)(ii), 45 CFR §46.108(a), 45 CFR §46.113
7.3 32 CFR §219.103(b)(5), 32 CFR §219.113, 32 CFR §219.108(a)